US 12,213,968 B2
Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea
Michael D. Kaufman, Waltham, MA (US); Scott Bone, Bend, OR (US); Corey Bloom, Bend, OR (US); and Fred Jordan, Bend, OR (US)
Assigned to Deciphera Pharmaceuticals, LLC, Waltham, MA (US)
Filed by Deciphera Pharmaceuticals, LLC, Waltham, MA (US)
Filed on Aug. 6, 2024, as Appl. No. 18/795,731.
Application 18/795,731 is a continuation of application No. 18/758,007, filed on Jun. 28, 2024.
Application 18/758,007 is a continuation of application No. 18/518,093, filed on Nov. 22, 2023, granted, now 12,064,422.
Application 18/518,093 is a continuation of application No. 18/448,312, filed on Aug. 11, 2023, granted, now 11,903,933, issued on Feb. 20, 2024.
Application 18/448,312 is a continuation of application No. 18/178,789, filed on Mar. 6, 2023, granted, now 11,793,795, issued on Oct. 24, 2023.
Application 18/178,789 is a continuation of application No. 18/148,766, filed on Dec. 30, 2022, granted, now 11,896,585, issued on Feb. 13, 2024.
Application 18/148,766 is a continuation of application No. 17/735,820, filed on May 3, 2022, granted, now 11,612,591, issued on Mar. 28, 2023.
Application 17/735,820 is a continuation of application No. 17/180,241, filed on Feb. 19, 2021, granted, now 11,395,818, issued on Jul. 26, 2022.
Application 17/180,241 is a continuation of application No. PCT/US2020/067560, filed on Dec. 30, 2020.
Claims priority of provisional application 62/968,695, filed on Jan. 31, 2020.
Claims priority of provisional application 62/968,724, filed on Jan. 31, 2020.
Claims priority of provisional application 62/955,062, filed on Dec. 30, 2019.
Claims priority of provisional application 62/955,073, filed on Dec. 30, 2019.
Prior Publication US 2024/0390345 A1, Nov. 28, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/4375 (2006.01); A61K 9/00 (2006.01); A61K 9/10 (2006.01); A61K 47/38 (2006.01)
CPC A61K 31/4375 (2013.01) [A61K 9/0053 (2013.01); A61K 9/10 (2013.01); A61K 47/38 (2013.01)] 18 Claims
 
1. A pharmaceutical composition comprising:
a solid dispersion comprising: a compound represented by Formula (I) or pharmaceutically acceptable salt thereof,

OG Complex Work Unit Chemistry
and hydroxypropylmethyl cellulose acetate succinate; and
wherein a compound represented by Formula (II):

OG Complex Work Unit Chemistry
is present in an amount equal to or less than about 10% by weight based on the weight of the compound of Formula (I) present in the composition.